Therefore, we systematically summarized the outcomes of LC patients with COPD after PD-1/PD-L1 inhibitor therapy and explored the impact of the tumor immune microenvironment (TIME) regulated by COPD on LC immunotherapy. This evidence concerns the gene PDCD1 and laryngotracheoesophageal cleft.